CFHR3 and atypical hemolytic-uremic syndrome: According to the gene association studies mentioned before, therapeutic inhibition of FHR-3 could be beneficial in AMD or IgAN, while a drug-dependent increase of FHR-3 activity could be a potential strategy for treatment of aHUS and SLE.